Rare and inherited diseases affect millions of patients worldwide, many of whom wait years for a diagnosis. Germline genomic testing, from targeted panels to exomes and genomes, has become central to shortening that diagnostic journey, provided labs can efficiently prioritize the variants that explain each patient's phenotype.
In this section, you will find our articles on rare and inherited disease genomics: germline variant interpretation, phenotype-driven prioritization, CNV detection, case studies from diagnostic labs, and updates on how SeqOne helps teams reach more diagnoses, faster.

Meet UP²-SV: a dedicated AI pathogenicity classifier for structural variants, trained on 65,000+ ClinVar SVs and validated on a clinical cohort with 97.6% sensitivity. AI-powered prioritization now spans the full variant spectrum.
A Spanish hospital ended a patient's 30-year diagnostic odyssey by combining Agilent's advanced exome sequencing with SeqOne's AI platform, uncovering a rare DMD gene duplication that had eluded detection for decades.

Genekor Medical, a Romanian diagnostics lab, uses SeqOne's platform to make HRD testing a routine clinical workflow. Using shallow whole genome sequencing and automated FASTQ-to-GIS analysis, they've cut complexity and costs, proving that reliable precision oncology testing is achievable for regional labs beyond major European hubs.